Marshall Wace LLP Has $83,000 Stake in FibroBiologics, Inc. (NASDAQ:FBLG)

Marshall Wace LLP trimmed its position in shares of FibroBiologics, Inc. (NASDAQ:FBLG) by 67.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,702 shares of the company’s stock after selling 35,323 shares during the period. Marshall Wace LLP’s holdings in FibroBiologics were worth $83,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Mercer Global Advisors Inc. ADV acquired a new stake in FibroBiologics during the second quarter worth about $51,000. Cahaba Wealth Management Inc. bought a new position in shares of FibroBiologics in the second quarter worth about $73,000. Saxon Interests Inc. bought a new position in shares of FibroBiologics in the second quarter worth about $106,000. Rhumbline Advisers bought a new position in shares of FibroBiologics in the second quarter worth about $115,000. Finally, ERn Financial LLC bought a new position in shares of FibroBiologics in the second quarter worth about $159,000.

Wall Street Analyst Weigh In

A number of research firms have recently commented on FBLG. EF Hutton Acquisition Co. I raised shares of FibroBiologics to a “strong-buy” rating in a report on Wednesday, September 4th. Maxim Group began coverage on shares of FibroBiologics in a report on Tuesday, September 24th. They issued a “buy” rating and a $12.00 target price for the company.

FibroBiologics Trading Up 12.1 %

Shares of NASDAQ FBLG opened at $2.60 on Monday. The company has a 50 day simple moving average of $2.44 and a 200 day simple moving average of $6.26. FibroBiologics, Inc. has a 1 year low of $1.08 and a 1 year high of $55.00.

FibroBiologics (NASDAQ:FBLG) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09). As a group, research analysts expect that FibroBiologics, Inc. will post -0.37 EPS for the current fiscal year.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.